 GILD | Gilead Sciences Inc. announced the completion of the previously announced, on Nov 21, 2011, transaction for Royal Merger Sub II Inc., a wholly-owned subsidiary of Gilead, to acquire Pharmasset Inc. for $137 per share in cash, or $11.2 billion in the aggregate. As a result of the completion of the merger, Pharmasset has become a wholly-owned subsidiary of Gilead and the common stock of Pharmasset will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market on Jan 17, 2012. |
Recent Events: M&A Close
Gilead Sciences Completes Acquisition of Pharmasset for $11.2B
January 17, 2012
